Literature DB >> 17034377

Treatment patterns and cost of nonmelanoma skin cancer management.

G John Chen1, Christopher B Yelverton, Sudhir S Polisetty, Tamara S Housman, Phillip M Williford, Hoa V Teuschler, Steven R Feldman.   

Abstract

INTRODUCTION: Nonmelanoma skin cancer (NMSC) is the most common form of cancer in the United States, more common than all other cancers combined. The factors that affect the cost of skin cancer management are not well defined.
OBJECTIVE: The objective was to estimate cost of episodes of NMSC care and the factors that impact those costs.
DESIGN: Medicare Current Beneficiary Survey (MCBS) data from 1999 to 2000 were used to assess costs of episodes of NMSC care. MCBS estimates of the number of episodes occurring in three service settings (physician's office, outpatient/ambulatory surgical center, or hospital) and demographics were obtained.
RESULTS: There were 497 episodes of care in 372 patients. Half the episodes were treated by dermatologists, and two-thirds were managed in physicians' offices. The mean episode cost for management in the office setting was 500 dollars (SD, +/- 487 dollars), and costs were higher when the episodes were treated in either the ambulatory surgical center or the hospital settings, 935 dollars (SD, +/- 456 dollars) and 4,345 dollars (SD, +/- 4939 dollars), respectively.
CONCLUSION: With the rising incidence and cost of NMSC to Medicare, it is increasingly important to preserve the low-cost management of this disease. Maintaining care of NMSC in the office-based setting is more cost-efficient than utilizing ambulatory surgical centers or hospital operating rooms.

Entities:  

Mesh:

Year:  2006        PMID: 17034377     DOI: 10.1111/j.1524-4725.2006.32288.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting.

Authors:  Leslie S Wilson; Mark Pregenzer; Rituparna Basu; Daniel Bertenthal; Jeanette Torres; Maryam Asgari; Mary-Margaret Chren
Journal:  Dermatol Surg       Date:  2011-12-06       Impact factor: 3.398

2.  Evidence that Gsta4 modifies susceptibility to skin tumor development in mice and humans.

Authors:  Erika L Abel; Joe M Angel; Penny K Riggs; Laura Langfield; Herng-Hsiang Lo; Maria D Person; Yogesh C Awasthi; Li-E Wang; Sara S Strom; Qingyi Wei; John DiGiovanni
Journal:  J Natl Cancer Inst       Date:  2010-10-21       Impact factor: 13.506

3.  Registration in the Danish Regional Nonmelanoma Skin Cancer Dermatology Database: completeness of registration and accuracy of key variables.

Authors:  Anna L Lamberg; Deirdre Cronin-Fenton; Anne B Olesen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

4.  Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery.

Authors:  Anokhi Jambusaria-Pahlajani; Chrysalyne D Schmults; Christopher J Miller; Daniel Shin; Jennifer Williams; Shanu K Kurd; Joel M Gelfand
Journal:  Dermatol Surg       Date:  2008-11-19       Impact factor: 3.398

5.  Traditional versus streamlined management of basal cell carcinoma (BCC): A cost analysis.

Authors:  Xinyuan Wu; Elena B Elkin; Chih-Shan Jason Chen; Ashfaq Marghoob
Journal:  J Am Acad Dermatol       Date:  2015-09-02       Impact factor: 11.527

Review 6.  Investigative Landscape in Advanced Non-Melanoma Skin Cancers.

Authors:  Priyanka Reddy; Min Yao; Monaliben Patel
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

7.  MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma.

Authors:  E Sonkoly; J Lovén; N Xu; F Meisgen; T Wei; P Brodin; V Jaks; M Kasper; T Shimokawa; M Harada; J Heilborn; M-A Hedblad; A Hippe; D Grandér; B Homey; P G Zaphiropoulos; M Arsenian-Henriksson; M Ståhle; A Pivarcsi
Journal:  Oncogenesis       Date:  2012-03-12       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.